Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 10/20 | 0.55 |
| ▸ | F2 | P00734 | 3/20 | 0.54 |
| ▸ | CTSG | P08311 | 2/20 | 0.54 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.46 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.46 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.46 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.46 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.46 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.46 |
| ▸ | PREP | P48147 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5353802 | 0.85 | PSEN1 (0.59) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3711815 | 0.82 | PREP (0.48) | ELANEF2PSEN1PSEN2APH1B | |
| SCHEMBL8156466 | 0.81 | PREP (0.47) | ELANEPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3029470 | 0.79 | HTR2C (0.53) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL29606975 | 0.79 | ELANE (0.52) | ELANEF2CTSGPSEN1PSEN2 | |
| SCHEMBL30440090 | 0.78 | FKBP1A (0.50) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL23478113 | 0.78 | PSEN1 (0.62) | ELANEPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL8132766 | 0.77 | ELANE (0.36) | ELANECTSGPSEN1PSEN2APH1B | |
| SCHEMBL31460272 | 0.77 | ELANE (0.54) | ELANEF2CTSGPREPNPC1 | |
| SCHEMBL1660359 | 0.77 | ELANE (0.55) | ELANEF2CTSGPSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192614-A1 | METHOD FOR PREPARATION OF TRANS-N-BENZYLOXYCARBONYL-(3-HYDROXY-2-PIPERIDINYL)-2-PROPANONE AS INTERMEDIATE OF HALOFUGINONE | CHENGDA PHARMACEUTICALS CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
| CN-109956966-B | Method for synthesizing key chiral intermediate of dichroine | 复旦大学 | 2021-05-04 | — | — | CN | disclosed |
| CN-109956966-A | A method of synthesis orixine key chiral intermediate | 复旦大学 | 2019-07-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192614-A1 | METHOD FOR PREPARATION OF TRANS-N-BENZYLOXYCARBONYL-(3-HYDROXY-2-PIPERIDINYL)-2-PROPANONE AS INTERMEDIATE OF HALOFUGINONE | TALDO1, RPL22, RPS20 | ELANE 994/4885F2 1083/4885CTSG 2227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.